Takeda Pharmaceutical (TAK) Amortization - Intangibles (2019 - 2026)

Takeda Pharmaceutical's Amortization - Intangibles history runs 7 years deep, the most recent figure standing at $8.4 billion for Q1 2026.

• On a quarterly basis, Amortization - Intangibles rose 1026.96% year-over-year to $8.4 billion in Q1 2026; TTM through Mar 2026 was $3.8 billion, a 169.25% increase from a year earlier, with the FY2026 full-year figure at $4.2 billion, changed 0.33% from the prior year.
• Amortization - Intangibles improved to $8.4 billion in Q1 2026 per TAK's latest filing, from -$887.0 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $8.4 billion in Q1 2026 and bottomed at -$2.8 billion in Q3 2025.
• The 5-year median for Amortization - Intangibles is -$933.3 million (2023), against an average of -$783.7 million.
• Across the five-year window, Amortization - Intangibles retreated 11.69% in 2023 and jumped 1026.96% in 2026, its largest moves.
• Year by year, Amortization - Intangibles stood at -$810.5 million in 2022, then slipped by 11.69% to -$905.2 million in 2023, then increased by 0.81% to -$897.9 million in 2024, then advanced by 1.21% to -$887.0 million in 2025, then jumped by 1049.44% to $8.4 billion in 2026.
• Per Business Quant, the three latest TAK Amortization - Intangibles figures stand at $8.4 billion (Q1 2026), -$887.0 million (Q4 2025), and -$2.8 billion (Q3 2025).